vs
Strata Critical Medical, Inc.（SRTA）与GeneDx Holdings Corp.（WGS）财务数据对比。点击上方公司名可切换其他公司
GeneDx Holdings Corp.的季度营收约是Strata Critical Medical, Inc.的5.3倍（$121.0M vs $22.7M）。Strata Critical Medical, Inc.同比增速更快（361.2% vs 26.5%）。GeneDx Holdings Corp.自由现金流更多（$-7.4M vs $-10.2M）。过去两年GeneDx Holdings Corp.的营收复合增速更高（39.2% vs -33.6%）
Strata Critical Medical, Inc.是一家医疗技术企业，设计、生产及销售用于重症监护、麻醉及外科场景的一次性医疗用品，主要服务北美及部分欧洲地区的医疗机构，专注提升患者安全与临床诊疗效率。
GeneDx是一家基因检测企业，2000年由美国国立卫生研究院（NIH）的两位科学家Sherri Bale和John Compton创立，创立初衷是为当时没有商业化检测方案的罕见病及极罕见病患者和家属提供临床诊断服务。公司最初设立于马里兰州及该州蒙哥马利县扶持的生物技术孵化器技术开发中心。
SRTA vs WGS — 直观对比
营收规模更大
WGS
是对方的5.3倍
$22.7M
营收增速更快
SRTA
高出334.7%
26.5%
自由现金流更多
WGS
多$2.7M
$-10.2M
两年增速更快
WGS
近两年复合增速
-33.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $22.7M | $121.0M |
| 净利润 | — | $-17.7M |
| 毛利率 | -0.9% | 69.6% |
| 营业利润率 | -18.4% | -11.8% |
| 净利率 | — | -14.6% |
| 营收同比 | 361.2% | 26.5% |
| 净利润同比 | — | -424.9% |
| 每股收益（稀释后） | $-0.11 | $-0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SRTAWGS
| Q4 25 | $22.7M | $121.0M | ||
| Q3 25 | $49.3M | $116.7M | ||
| Q2 25 | $70.8M | $102.7M | ||
| Q1 25 | $54.3M | $87.1M | ||
| Q4 24 | $-8.7M | $95.6M | ||
| Q3 24 | $36.1M | $76.9M | ||
| Q2 24 | $67.9M | $70.5M | ||
| Q1 24 | $51.5M | $62.4M |
净利润SRTAWGS
| Q4 25 | — | $-17.7M | ||
| Q3 25 | $57.4M | $-7.6M | ||
| Q2 25 | $-3.7M | $10.8M | ||
| Q1 25 | $-3.5M | $-6.5M | ||
| Q4 24 | — | $5.4M | ||
| Q3 24 | $-2.0M | $-8.3M | ||
| Q2 24 | $-11.3M | $-29.2M | ||
| Q1 24 | $-4.2M | $-20.2M |
毛利率SRTAWGS
| Q4 25 | -0.9% | 69.6% | ||
| Q3 25 | 23.6% | 72.4% | ||
| Q2 25 | 25.1% | 69.0% | ||
| Q1 25 | 22.1% | 67.1% | ||
| Q4 24 | — | 69.2% | ||
| Q3 24 | 20.8% | 62.2% | ||
| Q2 24 | 24.1% | 60.9% | ||
| Q1 24 | 19.7% | 59.9% |
营业利润率SRTAWGS
| Q4 25 | -18.4% | -11.8% | ||
| Q3 25 | -11.4% | -2.8% | ||
| Q2 25 | -7.0% | 8.7% | ||
| Q1 25 | -14.0% | -5.2% | ||
| Q4 24 | — | 9.2% | ||
| Q3 24 | -19.7% | -10.1% | ||
| Q2 24 | -17.9% | -15.0% | ||
| Q1 24 | -19.2% | -21.9% |
净利率SRTAWGS
| Q4 25 | — | -14.6% | ||
| Q3 25 | 116.5% | -6.5% | ||
| Q2 25 | -5.3% | 10.5% | ||
| Q1 25 | -6.4% | -7.5% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | -5.4% | -10.8% | ||
| Q2 24 | -16.7% | -41.4% | ||
| Q1 24 | -8.2% | -32.4% |
每股收益（稀释后）SRTAWGS
| Q4 25 | $-0.11 | $-0.59 | ||
| Q3 25 | $0.70 | $-0.27 | ||
| Q2 25 | $-0.05 | $0.36 | ||
| Q1 25 | $-0.04 | $-0.23 | ||
| Q4 24 | $-0.11 | $0.25 | ||
| Q3 24 | $-0.03 | $-0.31 | ||
| Q2 24 | $-0.15 | $-1.10 | ||
| Q1 24 | $-0.06 | $-0.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $31.0M | $171.3M |
| 总债务越低越好 | — | $54.5M |
| 股东权益账面价值 | $279.1M | $308.2M |
| 总资产 | $325.5M | $523.7M |
| 负债/权益比越低杠杆越低 | — | 0.18× |
8季度趋势，按日历期对齐
现金及短期投资SRTAWGS
| Q4 25 | $31.0M | $171.3M | ||
| Q3 25 | $22.8M | $155.1M | ||
| Q2 25 | $58.8M | $134.6M | ||
| Q1 25 | $34.8M | $159.2M | ||
| Q4 24 | $18.4M | $141.2M | ||
| Q3 24 | $20.0M | $116.5M | ||
| Q2 24 | $26.3M | $106.9M | ||
| Q1 24 | $36.8M | $112.9M |
总债务SRTAWGS
| Q4 25 | — | $54.5M | ||
| Q3 25 | — | $54.8M | ||
| Q2 25 | — | $55.1M | ||
| Q1 25 | — | $55.5M | ||
| Q4 24 | — | $55.8M | ||
| Q3 24 | — | $56.1M | ||
| Q2 24 | — | $56.3M | ||
| Q1 24 | — | $56.3M |
股东权益SRTAWGS
| Q4 25 | $279.1M | $308.2M | ||
| Q3 25 | $283.0M | $292.3M | ||
| Q2 25 | $223.1M | $277.1M | ||
| Q1 25 | $219.7M | $257.4M | ||
| Q4 24 | $221.9M | $245.2M | ||
| Q3 24 | $233.5M | $204.5M | ||
| Q2 24 | $229.4M | $194.0M | ||
| Q1 24 | $236.6M | $207.2M |
总资产SRTAWGS
| Q4 25 | $325.5M | $523.7M | ||
| Q3 25 | $335.1M | $493.9M | ||
| Q2 25 | $257.9M | $463.9M | ||
| Q1 25 | $250.6M | $446.4M | ||
| Q4 24 | $256.7M | $419.4M | ||
| Q3 24 | $282.9M | $408.8M | ||
| Q2 24 | $280.3M | $389.1M | ||
| Q1 24 | $282.8M | $394.5M |
负债/权益比SRTAWGS
| Q4 25 | — | 0.18× | ||
| Q3 25 | — | 0.19× | ||
| Q2 25 | — | 0.20× | ||
| Q1 25 | — | 0.22× | ||
| Q4 24 | — | 0.23× | ||
| Q3 24 | — | 0.27× | ||
| Q2 24 | — | 0.29× | ||
| Q1 24 | — | 0.27× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-8.3M | $-3.1M |
| 自由现金流经营现金流 - 资本支出 | $-10.2M | $-7.4M |
| 自由现金流率自由现金流/营收 | -44.7% | -6.1% |
| 资本支出强度资本支出/营收 | 8.1% | 3.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-58.5M | $14.3M |
8季度趋势，按日历期对齐
经营现金流SRTAWGS
| Q4 25 | $-8.3M | $-3.1M | ||
| Q3 25 | $-37.3M | $15.8M | ||
| Q2 25 | $-3.1M | $10.4M | ||
| Q1 25 | $-246.0K | $10.2M | ||
| Q4 24 | $-1.8M | $-3.2M | ||
| Q3 24 | $6.4M | $-4.4M | ||
| Q2 24 | $8.4M | $-4.5M | ||
| Q1 24 | $-15.6M | $-16.4M |
自由现金流SRTAWGS
| Q4 25 | $-10.2M | $-7.4M | ||
| Q3 25 | $-40.1M | $9.6M | ||
| Q2 25 | $-5.4M | $8.1M | ||
| Q1 25 | $-2.9M | $4.1M | ||
| Q4 24 | $-6.3M | $-6.2M | ||
| Q3 24 | $-3.0M | $-5.0M | ||
| Q2 24 | $-7.7M | $-5.9M | ||
| Q1 24 | $-16.4M | $-16.9M |
自由现金流率SRTAWGS
| Q4 25 | -44.7% | -6.1% | ||
| Q3 25 | -81.4% | 8.2% | ||
| Q2 25 | -7.6% | 7.8% | ||
| Q1 25 | -5.3% | 4.7% | ||
| Q4 24 | 72.7% | -6.5% | ||
| Q3 24 | -8.2% | -6.6% | ||
| Q2 24 | -11.4% | -8.3% | ||
| Q1 24 | -31.8% | -27.0% |
资本支出强度SRTAWGS
| Q4 25 | 8.1% | 3.6% | ||
| Q3 25 | 5.7% | 5.3% | ||
| Q2 25 | 3.2% | 2.3% | ||
| Q1 25 | 4.8% | 7.0% | ||
| Q4 24 | -52.6% | 3.2% | ||
| Q3 24 | 25.8% | 0.8% | ||
| Q2 24 | 23.8% | 1.9% | ||
| Q1 24 | 1.6% | 0.7% |
现金转化率SRTAWGS
| Q4 25 | — | — | ||
| Q3 25 | -0.65× | — | ||
| Q2 25 | — | 0.96× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -0.59× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SRTA
| Other Clinical | $11.4M | 50% |
| Transplant Clinical | $9.0M | 39% |
| Other | $2.4M | 11% |
WGS
| Diagnostic Test Third Party Insurance | $101.1M | 84% |
| Diagnostic Test Institutional Customers | $15.5M | 13% |
| Other | $3.4M | 3% |
